TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02821520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conbercept
Description: At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial PDT
Description: At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed PDT
Description: PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
Study: NCT03625011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
Study: NCT03189771

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: occlusal surface reduction
Description: occlusal surface reduction after single visit root canal treatment
Study: NCT02100657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Study: NCT01937767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT03189771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal surface reduction
Description: occlusal surface reduction after single visit root canal treatment
Study: NCT03174093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCh AFib application
Description: The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
Study: NCT00376480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood lymphocyte therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT01937767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study: NCT02100657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT03650751

Intervention type: OTHER
Intervention: Nursing observation indexes
Description: It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
Study: NCT02584166

Intervention type: BEHAVIORAL
Intervention: multifaceted program
Description: This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
Study: NCT03365063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Knowledge Translation
Description: 1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids.
Study: NCT02100657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01311206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial blood flow restriction
Description: Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise without partial blood flow restriction
Description: Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
Study: NCT00003369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: 260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
Study: NCT03498001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 agonists
Description: Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up by phone
Description: at 2 and 4 mois
Study: NCT03753490

Intervention type: OTHER
Group type: OTHER
Intervention: ABC score guided therapy
Description: In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
Study: NCT00376480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT01561079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
Study: NCT02261415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: 1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
Study: NCT02224014

Intervention type: DRUG
Intervention: Lendormin D tablets
Study: NCT02602249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1-gene-DC-CTL
Description: MUC1-gene-DC-CTL will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1-peptide-DC-CTL
Description: MUC1-peptide-DC-CTL will be used against tumor cells.
Study: NCT02794961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight
Study: NCT01757080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory performance assessment with ergospirometry test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory performance assessment with ergospirometry test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biochemical analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biochemical analysis
Study: NCT00433654

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Pulse Generator (IPG) and Pacing Leads (wires)
Description: Pacer and leads
Study: NCT01214564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel
Description: 0.05%
Study: NCT00672152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 derived peptides
Description: WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~* WT peptide #1: HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs.
Study: NCT04069390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARDIOSKIN - Short record
Description: A short record (max 2H15) is performed with Cardioskin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioskin - long record
Description: A long record (max 8H) is performed with Cardioskin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronaute - long record
Description: A long record (max 8H) is performed with Neuronaute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronaute -short record
Description: A short record (max 2H15) is performed with Neuronaute
Study: NCT03312803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini autogenous skin graft
Description: mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini autogenous skin graft
Description: mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
Study: NCT03219437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: capsule
Study: NCT03259347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Therapy
Description: Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based Therapy
Description: Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
Study: NCT01235273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: growth hormone administration
Study: NCT00433654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Pulse Generator (IPG) and Pacing Leads (wires)
Description: Pacer and leads
Study: NCT03026504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4 milligrams oral Baricitinib daily for 52 weeks
Study: NCT03112837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus, Bifidobacterium and Enterococcus
Description: 3 pills two times a day during the whole treatment
Study: NCT03983876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease
Study: NCT01842061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Living Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT03828838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 PSMA-617
Description: Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
Study: NCT01881620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBI TEP : PET / enhanced CT scan
Description: diagnostic imaging exam
Study: NCT04389801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferal 500 MG Injection
Description: iron chelating agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desferal 500 MG Injection
Description: iron chelating agent
Study: NCT02951546

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat diet
Description: In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type).
Study: NCT01554878

Intervention type: PROCEDURE
Intervention: knee surgery
Description: Reparative, replacement or regenerative techniques, with or without associated osteotomy.
Study: NCT00698126

Intervention type: DRUG
Intervention: soluble human insulin
Description: Observational study; use of the products as in the normal clinical practice conditions

Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Observational study; use of the products as in the normal clinical practice conditions
Study: NCT00084682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study: NCT03375658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDWS Intervension
Description: Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
Study: NCT02771392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic Tetracaine
Description: 1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
Study: NCT03330132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard inactivated influenza vaccine (NH formulation)
Description: 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
Study: NCT00252148

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ADMVA
Description: experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ADMVA
Description: experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
Study: NCT03330132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard inactivated influenza vaccine (NH formulation)
Description: 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard inactivated influenza vaccine (NH formulation)
Description: 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard inactivated influenza vaccine (NH formulation)
Description: 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard inactivated influenza vaccine (NH formulation)
Description: 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
Study: NCT00506311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: Tisseel applied externally to the dissected groin area.